HAMBURG, Germany, April 7, 2015 /PRNewswire/ --
Past General Partner and Chief Administrative Officer of the Equities Division of Goldman, Sachs & Co. and current member of the Board of Directors of the Pennsylvania-based Geisinger Health System will advise Indivumed, GmbH and its affiliates during the company's global expansion campaign.
Hartmut Juhl, MD, President and Chief Executive Officer of Indivumed, GmbH, announced today that William R. Gruver, the Howard I. Scott Chair in Global Commerce, Strategy, and Leadership at Bucknell University, will chair the Indivumed, GmbH Business Advisory Committee, assisting in the development and implementation of a transformational expansion of the company's global oncology research network.
Professor Gruver, an international strategic consultant for businesses in the U.S., Europe, and Asia, also serves on the boards of Hirtle, Callaghan & Co., a USD 25 billion investment firm, and Geisinger Health System, one of the foremost nationally recognized integrated health systems in the United States. He also serves as a national arbitrator for the Financial Industry Regulatory Authority (FINRA).
When asked to comment, Dr. Juhl said of Professor Gruver: "Bill brings to INDIVUMED an international business perspective that will allow our company to grow within our three target markets, the United States, Europe, and Asia." Juhl went on to say, "The fuel for our growth will come largely from venture investments. Bill understands this world, and I will rely heavily on his judgment and perspective."
When contacted, Gruver stated of this new collaboration: "INDIVUMED is ideally positioned at the junction of opportunity and competence. The biomedical research market is responding quickly and generously to the acquisition and analysis of high quality data to attack the catastrophic failure rates of new drugs, particularly in cancer. INDIVUMED has perfected, over the past 12 years, the practice of securing high quality tissue and data in a manner far advanced over their competitors." He continued by stating that: "Hartmut and his team represent a world class cancer biologics company, built on German precision and commitment to excellence. I am excited and honored to be a part of this unique team."
INDIVUMED is an integrated oncology company, based in Hamburg, Germany, leveraging its leading oncology biorepository expertise with pre-clinical, clinical, and diagnostic laboratory expertise aiming to develop individualized cancer therapies. INDIVUMED provides products and services to obtain an in-depth understanding of the underlying mechanisms of a patient's cancer and addresses several important demands in translational research and molecular diagnostics to support the implementation of personalized healthcare. INDIVUMED offers a unique combination of capabilities that can significantly contribute to the identification of new biomarkers and drug targets, development of novel companion diagnostics to guide treatment decisions, collection of information for defining the right treatment for every patient's unique biology, and ultimately to the cure of cancer. INDIVUMED partners with nine hospitals and 20 clinics in Hamburg, Germany, as well as Georgetown University Medical Center, Washington Hospital Center, and Geisinger Health System in the United States. The company aims to expand its current 20,000 patient biorepository to in excess of 150,000 patients globally within the next five years.
For more information, please visit http://www.indivumed.com.
Marketing Communications Manager
Falkenried 88, Building D
SOURCE Indivumed GmbH